Thai Drug Maker Says Second H1N1 Seed Virus Produces Higher Yield
This article was originally published in PharmAsia News
Executive Summary
A Thailand drug maker reports its second batch of seed virus has proved successful in delivering a higher yield of H1N1 flu vaccine. The Government Pharmaceutical Organization's director said the quality of seed virus liquid in the second batch also is better than that of the first. The second batch of seed virus was sought from a foreign supplier after the first provided a yield considered too low to be useful. (Click here for more
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.